0 537

Cited 3 times in

Comparative effect on platelet function of a fixed-dose aspirin and clopidogrel combination versus separate formulations in patients with coronary artery disease: A phase IV, multicenter, prospective, 4-week non-inferiority trial

Authors
 Pyung Chun Oh  ;  Taehoon Ahn  ;  Dong Woon Kim  ;  Bum-Kee Hong  ;  Dong-Soo Kim  ;  Jun Kwan  ;  Cheol Ung Choi  ;  Yong-Mo Yang  ;  Jang Ho Bae  ;  Kyung Tae Jung  ;  Woong Gil Choi  ;  Dong Woon Jeon  ;  Deok Kyu Cho  ;  Wook Bum Pyun  ;  Kwang Soo Cha  ;  Tae-Joon Cha  ;  Kook Jin Chun  ;  Young Dae Kim  ;  Byung Soo Kim  ;  Doo-Il Kim  ;  Tae Ik Kim 
Citation
 INTERNATIONAL JOURNAL OF CARDIOLOGY, Vol.202(2016) : 331-335, 2016 
Journal Title
INTERNATIONAL JOURNAL OF CARDIOLOGY
ISSN
 0167-5273 
Issue Date
2016
MeSH
Aspirin/administration & dosage* ; Coronary Artery Disease/drug therapy* ; Drug Combinations ; Drug-Eluting Stents ; Female ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/administration & dosage* ; Platelet Function Tests ; Prospective Studies ; Ticlopidine/administration & dosage ; Ticlopidine/analogs & derivatives* ; Treatment Outcome
Keywords
Aspirin ; Clopidogrel ; Fixed-dose combination ; Platelet function
Abstract
BACKGROUND/OBJECTIVES: The effect of aspirin and clopidogrel in a fixed-dose combination (FDC) on platelet function was compared with separate formulations in patients that had undergone percutaneous coronary intervention (PCI) with drug-eluting stent (DES).
METHODS: This was a phase IV, prospective, multicenter, single-arm, non-inferiority study. Patients that had taken aspirin 100 mg and clopidogrel 75 mg once daily as separate formulations for >6 months after PCI with DES were enrolled, and then switched to an aspirin/clopidogrel FDC once-daily for 4 weeks. Platelet reactivity was determined using the VerifyNow® P2Y12 assay at baseline (immediately prior to switching) and 4 weeks later.
RESULTS: A total of 648 patients (the full-analysis population; age, 63.6±9.0 years; male, 76.5%) finished the study, and 565 (the per-protocol population) completed without protocol violations. In the per-protocol population, the % inhibitions of P2Y12 and ARU were not significantly different between baseline and after 4 weeks of FDC treatment (29.2±20.0% to 29.0±19.9%, P=0.708; 445.1±69.2 to 446.2±63.0, P=0.799, respectively) and the difference in P2Y12 inhibition observed did not exceed the predetermined limit of non-inferiority (95% CI, -0.9 to 1.3). In the full-analysis population, the % inhibitions of P2Y12, PRU, and ARU were not significantly changed after 4 weeks of FDC treatment.
CONCLUSIONS: This study demonstrates that the efficacy of platelet inhibition by an aspirin/clopidogrel FDC was not inferior to that of separate aspirin and clopidogrel formulations in patients that had undergone PCI with DES.
Full Text
http://www.sciencedirect.com/science/article/pii/S0167527315304654
DOI
10.1016/j.ijcard.2015.09.024
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Hong, Bum Kee(홍범기) ORCID logo https://orcid.org/0000-0002-6456-0184
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/145501
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links